NASDAQ:VBIV - VBI Vaccines Stock Price, Forecast & News

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

VBI Vaccines Inc (NASDAQ:VBIV) announced its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.02. The biopharmaceutical company had revenue of $0.65 million for the quarter, compared to analysts' expectations of $0.90 million. VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%. View VBI Vaccines' Earnings History.

VBI Vaccines is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for VBI Vaccines.

3 brokerages have issued twelve-month price objectives for VBI Vaccines' shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate VBI Vaccines' share price to reach $4.33 in the next year. This suggests a possible upside of 218.6% from the stock's current price. View Analyst Price Targets for VBI Vaccines.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.

Headlines about VBIV stock have been trending somewhat negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VBI Vaccines earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for VBI Vaccines.

Some companies that are related to VBI Vaccines include Revance Therapeutics (RVNC), XBiotech (XBIT), Akebia Therapeutics (AKBA), Odonate Therapeutics (ODT), Amphastar Pharmaceuticals (AMPH), Gossamer Bio (GOSS), Applied Therapeutics (APLT), RAPT Therapeutics (RAPT), Phathom Pharmaceuticals (PHAT), Achillion Pharmaceuticals (ACHN), Radius Health (RDUS), G1 Therapeutics (GTHX), Aprea Therapeutics (APRE), Dova Pharmaceuticals (DOVA) and Kiniksa Pharmaceuticals (KNSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include QuickLogic (QUIK), Opko Health (OPK), Novavax (NVAX), Selecta Biosciences (SELB), Second Sight Medical Products (EYES), SCYNEXIS (SCYX), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Catalyst Pharmaceuticals (CPRX) and Biocept (BIOC).

VBI Vaccines' stock is owned by a number of of institutional and retail investors. Top institutional investors include First Midwest Bank Trust Division (0.80%), Premier Asset Management LLC (0.14%) and Wedbush Securities Inc. (0.01%). Company insiders that own VBI Vaccines stock include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Institutional Ownership Trends for VBI Vaccines.

VBIV stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Premier Asset Management LLC and Wedbush Securities Inc.. Company insiders that have bought VBI Vaccines stock in the last two years include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Insider Buying and Selling for VBI Vaccines.

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VBIV stock can currently be purchased for approximately $1.36.

VBI Vaccines has a market capitalization of $242.43 million and generates $3.36 million in revenue each year. The biopharmaceutical company earns $-63,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. VBI Vaccines employs 108 workers across the globe.View Additional Information About VBI Vaccines.

The official website for VBI Vaccines is http://www.vbivaccines.com/.

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]